Semaglutide vs Liraglutide
Weekly versus daily dosing within the GLP-1 class.
Semaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Liraglutide (GLP-1 receptor agonist)
A once-daily GLP-1 receptor agonist and the first GLP-1 approved specifically for obesity, with proven cardiovascular benefit.
| Attribute | Semaglutide | Liraglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | FDA-approved (Victoza for T2D; Saxenda for weight management) |
| Half-life | ~7 days | ~13 hours |
| Molecular weight | 4,113.6 Da | 3,751.2 Da |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | Activates the GLP-1 receptor to increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. |
| Legal status (US) | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Semaglutide and Liraglutide?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. Liraglutide: A once-daily GLP-1 receptor agonist and the first GLP-1 approved specifically for obesity, with proven cardiovascular benefit.
Which has stronger research evidence, Semaglutide or Liraglutide?
Semaglutide is rated Strong and Liraglutide is rated Strong for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are Semaglutide and Liraglutide FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Liraglutide: FDA-approved (Victoza for T2D; Saxenda for weight management).
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.